



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD – INITIAL PUBLIC OFFER

NeuroScientific Biopharmaceuticals Ltd (**Company**) provides the following confirmations to satisfy conditions for the admission of the Company's securities to quotation on ASX.

Unless otherwise stated, capitalised terms not defined in this announcement have the meaning given in the Prospectus (defined below).

Completion of Offer

The Company confirms that the initial public offer under the Company's prospectus dated 9 May 2018 (**Prospectus**) has closed fully-subscribed, and the Company has issued 30,000,000 fully paid ordinary shares (**Shares**) under the Public Offer.

Issue of Shares

In addition to the Shares issued pursuant to the Public Offer, the Company has also issued the following Shares as contemplated in the Prospectus:

- (a) 11,000,000 Shares to unrelated seed capitalists and related parties on conversion of 440,000 Convertible Notes;
- (b) 950,000 Shares to Directors on conversion of the Class A Performance Shares; and
- (c) 275,000 shares to Dr Anton Uvarov in settlement of outstanding Director's fees.